Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05709314 · ClinicalTrials.gov registry record · Phase 2
A Study of AMDX-2011P in Participants With CAA
A Phase 2 study of Cerebral Amyloid Angiopathy, sponsored by Amydis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05709314 is a Phase 2 study of Cerebral Amyloid Angiopathy that is actively recruiting participants, run by Amydis. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05709314, a Phase 2 study of Cerebral Amyloid Angiopathy, is actively recruiting participants, sponsored by Amydis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).
Conditions Studied
Interventions
- DRUG AMDX-2011P
Study Locations (1)
Arizona
- Associated Retina Consultants - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-07-09 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05709314
The ClinicalTrials.gov registry entry for NCT05709314 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amydis, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cerebral Amyloid Angiopathy appearing as the primary indexed condition, and to 1 intervention - of which AMDX-2011P is the first listed.
NCT05709314 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT05709314 about?
NCT05709314 is a clinical study titled "A Study of AMDX-2011P in Participants With CAA". The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).
What is the current status of trial NCT05709314?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2024-07-09. Estimated completion is 2026-12.
What conditions does trial NCT05709314 study?
This clinical trial studies the following conditions: Cerebral Amyloid Angiopathy.
What interventions are being tested in trial NCT05709314?
The interventions under investigation include: AMDX-2011P (DRUG).
Who is sponsoring clinical trial NCT05709314?
This trial is sponsored by Amydis, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05709314 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cerebral Amyloid Angiopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.